Caplin Point Laboratories Limited · NSE:CAPLIPOINT
Caplin Point Laboratories — Q3 FY24 Earnings Presentation
19 slides from Caplin Point Laboratories's earnings presentation, February 2024
Slide 1: Earnings Presentation Q3 FY24
EARNINGS PRESENTATION Q3 FY24 Rated #1 in India for “Most Consistent Profitable Growth across the last 10 years” Second Largest wealth creator for the decade ending 2020* February 2024 www.caplinpoint.net #Value Research magazine – Wealth Insight June 2022 issue *The Economic Times
Slide 2: Disclaimer
Disclaimer The Presentation is to provide the general background information about the Company’s activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any i
Slide 3: Q3 FY24 Income Statement
Q3 FY24 Income Statement Revenue Gross Profit EBITDA 17% 18% 29% YoY YoY YoY 436 246 245 158 159 410 208 124 372 Q3 FY23 Q2 FY24 Q3 FY24 Q3 FY23 Q2 FY24 Q3 FY24 Q3 FY23 Q2 FY24 Q3 FY24 EBIT PAT Earnings Per Share 30% 23% YoY YoY 146 146 116 120 15.13 15.44 112 97 12.86 Q3 FY23 Q2 FY24 Q3 FY24 Q3 FY2
Slide 4: Q3 FY24 Profit Margins
Q3 FY24 Profit Margins Gross Profit Margins (%) EBITDA Margins (%) 60.0% 36.7% 35.2% 55.9% 56.3% 32.0% Q3 FY23 Q2 FY24 Q3 FY24 Q3 FY23 Q2 FY24 Q3 FY24 EBIT Margins (%) PAT Margins (%) 33.9% 27.0% 32.2% 26.5% 29.0% 25.2% Q3 FY23 Q2 FY24 Q3 FY24 Q3 FY23 Q2 FY24 Q3 FY24 4
Slide 5: 9M FY24 Income Statement
9M FY24 Income Statement Revenue Gross Profit EBITDA 15% 20% 26% YoY YoY YoY 1,241 708 456 1,077 362 591 9M FY23 9M FY24 9M FY23 9M FY24 9M FY23 9M FY24 EBIT PAT Profit Margins 28% 23% YoY YoY 340 57.1% 419 54.8% 328 276 35.3% 32.2% 32.4% 29.2% 24.6% 26.4% 9M FY23 9M FY24 9M FY23 9M FY24 9M FY23 9M
Slide 6: Leadership Team
Leadership Team Chairman Perspectives Management Team Commenting on the recent performance, Mr. C.C. Paarthipan, Chairman of Caplin Dr. Sridhar Ganesan Mr. Vivek Partheeban Point Laboratories said: • Managing Director • Chief Operating Officer Consistency has always been a key area for our company a
Slide 7: Q3 FY24 Highlights (Emerging Markets)
Q3 FY24 Highlights (Emerging Markets) 01 03 05 Company's strong growth in Current breakup of revenue Company targets its first LatAm continues, with continued segments at LatAm: revenues from its own Oncology focus on Cashflow, Bottom Line, - Wholesalers : 55% site in Q4 FY24. Company has and Top Li
Slide 8: Q3 FY24 Highlights (US and Regulated markets)
Q3 FY24 Highlights (US and Regulated markets) 01 03 05 Caplin Steriles experiences The company currently has 13 Company receives its first Otic ANDAs under review, expecting strong revenue growth due to product approval from the FDA, expanded capacity from Line 5. 3-4 approvals in the coming slated
Slide 9: Evolution Over the Decades
Evolution Over the Decades Commences Capex expansion in multiple Work on Regulated Markets projects equaling INR 600 Incorporates Caplin Steriles Listed on Stock Started outsourcing from Injectable unit starts Started first commercial Cr. CRO wing Amaris Clinical USA Inc for launching own Exchange C
Slide 10: Research & Development Capabilities
Research & Development Capabilities 1 Caplin has 5 dedicated R&D setups (3 – DSIR approved and 2 under approval) R&D Expense (Rs. Crore) R&D Expense as a % of Operating Revenue 85 2 Continuous capex investment of over INR 550 Cr over last 7 years towards enhanced manufacturing and R&D capabilities,
Slide 11: Revenue Break up and Manufacturing Strategy
Revenue Break up and Manufacturing Strategy Revenue by Business Segment Revenue by Channel FY23 Operating Revenue (Emerging Markets) (Emerging Markets) 25% 15% 2% 75% 25% 55% 20% 83% Africa US LATAM Generic Branded Generic Wholesale Retail Institutional Caplin covers a wide spectrum of pharmaceutica
Slide 12: Generics and Branded Generics Product Mix
Generics and Branded Generics Product Mix Non-Steroidal Antiinflammatory Antihelminthics/ Dewormer Analgesic Drugs-NSAIDS Antibiotic and Antifungal Antihypertensive drug Electrolytes 12
Slide 13: Caplin Point Structure
Caplin Point Structure 100% Caplin Point Laboratories Subsidiary Caplin Steriles Ltd wholly Caplin Steriles USA Inc owned (BSE: 524742| NSE: CAPLIPOINT) (India) subsidiary (US) Manufacturing Units: Manufacturing Unit: Distribution: • CP I: Puducherry • CP IV: Gummidipoondi • Front-end office for the
Slide 14: Manufacturing and R&D Platform
Manufacturing and R&D Platform Tamil Nadu, India Location of Plants and Facilities 11 10 2 4 1. Puducherry (CP I) 8 75 2. Gummidipoondi (CP II) 3 3. Chengalpattu (CP III) 1 4. Gummudipoondi (CP IV) 5. Chennai (CP V) CP I CP III 6. Hyderabad (CP VI) Puducherry Chengalpattu 7. Chennai (CP VII) 8. Chen
Slide 15: Strategic Investments
Strategic Investments Project Summary Facility Location Product Target Market Status Timeline CP1, Caplin Point Unit-I Suthukeny, Softgel Existing Markets Completed Q4 FY23 Puducherry Line 5 – Injectable Vials Completed. Caplin Steriles CP4, and Pre-Filled Regulated Markets Line 6 – Q1 FY25 Phase II
Slide 16: Caplin Point’s Investment Case
Caplin Point’s Investment Case Core Business to show consistent Caplin’s core business which is focused on Latin America and Francophone Africa is expected to grow at a growth steady pace with industry-average margins and benchmark cashflows Aspiration is to have exceptional compliance record and fo
Slide 17: Experienced and Visionary Board of Directors
Experienced and Visionary Board of Directors Mr. C.C. Paarthipan Dr. Sridhar Ganesan D Sathya Narayanan Dr. C K Gariyali, IAS Dr. R Nagendran Mr S Deenadayalan Chairman Managing Director Independent Director Independent Director Independent Director Independent Director 30+ Years of experience in 35
Slide 18: P&L for the Q3 FY24 – Consolidated
P&L for the Q3 FY24 – Consolidated Value (INR Cr) Q3 FY24 Q3 FY23 YoY (%) Q2 FY24 QoQ (%) 9M FY24 9M FY23 YoY (%) Revenue from Operation 435.50 372.07 17.0% 410.06 6.2% 1,240.88 1,077.45 15.2% Other Income 17.18 14.15 20.43 49.65 44.58 Total Revenue 452.68 386.22 17.2% 430.49 5.2% 1,290.53 1,122.03
Slide 19: Investor Relations at Caplin
INVESTOR RELATIONS AT CAPLIN Mr G Venkatram [email protected] CHURCHGATE PARTNERS Rajiv Pandya / Paresh Rohra [email protected] 524742 CAPLIPOINT CIN: L24231TN1990PLC019053 ISIN: INE475E01026 |DUNS:86-148-4556 | WWW.CAPLINPOINT.NET ©2018, Caplin Point Laboratories Limited –
Caplin Point Laboratories — Q3 FY24 Earnings Presentation on 6ix